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PRIMARY BILIARY CHOLANGITIS IN 2016  
 
High-definition PBC: biology, models and therapeutic advances 
 
Gwilym J. Webb and Gideon M. Hirschfield * 
 
In 2016, obeticholic acid — a semisynthetic bile acid analogue — became the first 
new licensed therapy for patients with primary biliary cholangitis in over 20 years. 
This therapeutic came at a time of clarity over risk stratification and paralleled by 
better disease understanding through biliary and immunologic mechanistic insights.   
 
  
Key advances 
 
Patients with PBC are now the beneficiaries of stratified medicine which has aided 
clinical and research practice. 
 
Manipulation of the IFNγ pathway in mice led to an animal model of autoimmune 
cholangitis that recapitulates the female preponderance of primary biliary cholangitis 
(PBC)3 
 
Bile-salt-induced apoptosis is regulated by soluble adenylyl cyclase; dysregulation 
of anion exchanger 2 function sensitizes biliary epithelial cells to apoptosis by 
activating soluble adenylyl cyclase5 
 
Glycohenodeoxycholic acid reduces expression of anion exchanger 2 in biliary 
epithelial cells, inducing reactive oxygen species and enhancing epithelial cell 
senescence6 
 
A clinical trial supports the efficacy of obeticholic acid in the treatment of patients 
failing current care10, leading to a licensed therapeutic that is predicted to change the 
clinical course of PBC 
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Primary biliary cholangitis (PBC, formerly known as primary biliary cirrhosis) is an 
important but rare chronic immune-mediated liver disease. Currently, 1 in 1,000 women 
are estimated to live with PBC, with risks of disease progression to cirrhosis and liver 
failure, as well as symptoms associated with the disease (particularly pruritus and an 
association with fatigue)(1). In 2016, our understanding of PBC pathogenesis has 
continued to be further refined on the basis of elegant basic and clinical science, 
including the concept of high and low risk disease, particularly as recognized after 
evaluation of treatment response to the first line agent ursodeoxycholic acid(2).  
 
Increasingly, it is recognized that a multistep model of PBC pathogenesis can be 
identified (Fig. 1) that encompasses: a genetic risk for autoimmunity; environmental 
factors that might trigger a loss of immune tolerance and/or damage biliary epithelial cell 
integrity; biliary epithelial injury that subsequently alters bicarbonate production and 
jeopardizes normal barrier functions and apoptosis; a cycle of biliary epithelial response 
to injury that includes apoptosis, senescence and recruitment of inflammatory cells; 
ongoing ductopenia and added cholestasis; and ultimately, progressive liver fibrosis and 
cirrhosis (1) . In this setting, therapies for those stratified at high-risk of disease 
progression, despite ursodeoxycholic acid use, will be more or less effective, depending 
on when they are initiated and how they are delivered.  
 
Animal models of disease have always been a struggle in PBC, as attempting to 
recapitulate such a complex interaction of immunologic injury and localized tissue 
response is inevitably challenging. Murine autoimmune cholangitis has been the subject 
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of many models that have spanned genetic modification, as well as xenobiotic exposure, 
with each model recapitulating some, but not all, features of human disease. However, 
work from the Gershwin and Young groups this year(3) has made progress in developing a 
more meaningful disease model for study, and one that captures the gender distinction 
seen in PBC. This group studied mice characterized by prolonged chronic expression of 
IFNγ as a result of deletion of interferon 3'-untranslated region adenylate-uridylate-rich 
element (ARE). Interestingly, in this model, the ARE-Del-/- mice developed murine PBC 
characterised by female predominance, upregulation of total bile acids, spontaneous 
production of anti-mitochondrial antibodies and portal duct inflammation. Additionally, 
immune-transfer experiments (CD4+ T-cells from ARE-Del-/- mice to B6/Rag1-/- mice) 
induced portal and parenchymal inflammation. Overall, this work highlighted the 
importance of interferon signalling in initial PBC pathogenesis. Inflammatory responses 
mediated by T helper 1 cells have been recognized as critical for loss of immunologic 
tolerance and this data parallels a substantial understanding of PBC genetic risk that 
spans key immune-regulatory pathways including IL-12 and JAK–STAT signalling(4), 
pathways potentially additionally modifiable by estrogen exposure. 
 
A dichotomous understanding of PBC has often been raised between the 
importance of immunologic injury alongside cellular response to biliary injury and 
cholestasis. With more sophisticated experimental approaches, over time it seems that 
this distinction is beginning to blur and in a way that might indicate the best therapeutic 
approaches for the future. Notably, it has become relevant that the Cl-/HCO3- exchanger 
(AE2; anion exchanger 2) and an intact biliary glycocalyx are important in maintaining a 
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biliary HCO3- umbrella that protects against bile acid-induced cholangiocyte damage and 
apoptosis. In 2016, Chang et al.(5) explored this understanding further and demonstrated 
in vitro that soluble adenylyl cyclase, a bicarbonate sensor, regulates bile-salt-induced 
apoptosis in a manner dependent on intracellular Ca2+ stores, which are mediated by 
intrinsic apoptotic pathways. These findings suggest that downregulation of AE2 in PBC 
can sensitize cholangiocytes to apoptotic insults by activating soluble adenylyl cyclase. 
Intriguingly, in related work, Hisamoto et al.(6) found that hydrophobic bile acids 
suppress expression of AE2 in biliary epithelial cells and this suppression induced bile 
duct inflammation. The hydrophobic bile acid glycochenodeoxycholic acid reduced AE2 
expression in biliary epithelial cells by inducing reactive oxygen species and enhancing 
biliary epithelial cell senescence. Additionally, reduced AE2 expression upregulated the 
expression of CD40 and HLA-DR, as well as production of IL-6, IL-8 and CXCL10 from 
biliary epithelial cells in response to Toll-like receptor ligands (CXCL10 is secreted by 
several cell types in response to IFNγ). This work, therefore, equally highlights how 
changes to normal biliary epithelial cell physiology are relevant, not only to biliary 
epithelial cell response to injury, but also to subsequent signalling pathways leading to 
chronic inflammatory responses. The senescence-associated secretory phenotype of 
biliary epithelial cells might therefore be relevant in PBC and other cholestatic liver 
diseases, and changes in AE2 function could be a ‘bridge’ between the immune system 
(initiating and perpetuating pathways) and cholestasis. Additionally, that IL-17-positive T 
cells are detected in portal infiltrates close to inflamed bile ducts expressing the CCR6 
ligand CCL20 is already known (7). Cytokine-treated human cholangiocytes secrete 
CCL20 and induce CCR6-dependent migration of T helper 17 cells, suggesting that local 
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cholangiocyte chemokine secretion then localises these pathogenic and damaging cells to 
bile ducts(7). Equally intriguing is that CCL20 is a recognised genetic risk locus for PBC 
development, and so collectively may be a meaningful added target for intervention (4). 
 
Further advances in understanding the careful orchestration of liver injury have 
come from better appreciation of the gut–liver axis, with focus towards the farnesoid X 
receptor (FXR)–fibroblast growth factor (FGF)-19 signalling pathway. The nuclear bile 
acid receptor FXR is a central transcriptional sensor of bile acid metabolism and one key 
target gene in the gut is FGF19, which encodes an enterokine released into portal blood 
following bile acid binding to FXR. This axis is of interest because of the opportunity to 
augment the pathway for therapeutic benefit, with the goal of directing enhanced anti-
inflammatory, anti-fibrotic and anti-cholestatic mechanisms. In the liver, FGF-19 
regulates  intracellular pathways that inhibit cholesterol 7α-hydroxylase (CYP7A1), the 
rate limiting enzyme in bile acid synthesis (8). A noncancer-promoting FGF-19 variant 
(M70) has been developed as a potential new therapeutic for cholestatic liver diseases, 
which continues to inhibit bile acid synthesis and reduce excess hepatic bile acid 
accumulation(8). Thus, it is noteworthy that this year, in a further murine experiment by 
Zhou et al.(9), modulating bile acid metabolism in a mouse model of cholangiopathy with 
FGF-19 and M70 rapidly and effectively reversed liver injury, decreased hepatic 
inflammation and reduced biliary fibrosis. These effects seemed contingent on inhibition 
of hepatic expression of CYP7A1 and CYP27A1, genes encoding the enzymes responsible 
for key steps in the classic and alternate bile acid synthetic pathways. This approach is 
undergoing clinical trials spanning cholestatic liver disease and nonalcoholic fatty liver 
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disease.  
 
Convincing human data has finally, emerged over the past 5 years supporting 
clinical efficacy for the semisynthetic bile-acid-derived FXR agonist, obeticholic acid, 
such that 2016 culminated in a new internationally approved therapy for patients with 
PBC. In particular, data published in 2016 from a large clinical trial with obeticholic 
acid(10) added to previous clinical studies showing that FXR agonism has clear, durable 
effects on relevant markers of active cholestatic liver injury. Obeticholic acid reduces 
exposure to toxic hydrophobic bile acids by predicted and demonstrated falls in bile acid 
synthesis through direct and indirect (FGF-19) actions on CYP7A1-mediated bile acid 
synthesis, as well as bile acid excretion by hepatocytes. In conjunction with considerable 
academic work on surrogate markers of PBC disease course and outcome, the data from 
the obeticholic acid trials proved sufficient for product authorisation. Patients with PBC 
now have access to the first of, hopefully, many new generation treatments for their 
disease, which have arisen from collective ongoing efforts to finally understand PBC in 
high-definition. 
 
G. Webb and G. M. Hirschfield are at the Centre for Liver Research, National Institute 
for Health Research Birmingham Liver Biomedical Research Unit, University of 
Birmingham, Wolfson Drive, Birmingham B15 2TT, UK. 
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Figure 1. Converging themes in the pathophysiology and treatment of PBC 
Obeticholic acid downregulates bile acid production and limits further damage to small 
bile ducts through an inhibitory action on the expression of the bile acid synthetic 
enzymes CYP7A1 and CYP27A1, and through synthesis of fibroblast growth factor 
(FGF)-19 10. 2. Mice with targeted disruption of MDR2 have unchaperoned bile acids, 
which are more reactive and cause progressive damage to biliary epithelial cells (BEC) 
and liver fibrosis. FGF-19 and M70 act to reduce bile acid synthesis and reduce 
fibrogenesis 9. 3. Bile acids (glycochenodeoxycholic acid) downregulate the expression 
of AE2 through the formation of reactive oxygen species, which has multiple 
downstream effects including increased expression of the effector cytokines IL-6 and IL-
8, and the leukocyte chemoattractant CXCL10 6. 4. Through inhibition of AE2 activity 
and intracellular accumulation of bicarbonate, bile acids promote BEC apoptosis and 
make BEC more susceptible to non-bile-acid proapoptotic stimuli 5. 5. Dysregulated 
over-production of IFNγ in mice results in T-cell infiltration of periductular areas, the 
production of anti-mitochondrial antibody (AMA) in conjunction with B cells and the 
upregulation of bile acid production. The effects are more marked in female mice 
recapitulating the features of PBC 3.  
 
FGFR4, fibroblast growth factor receptor 4/klotho beta; FXR, farnesoid X receptor; PC, 
phosphatidylcholine; sAC, soluble adenylyl cyclase 
 
 
